Pamplona acquires majority stake in Alvogen

Pamplona Capital Management said Wednesday that it has purchased a majority stake in Alvogen. No financial terms were disclosed. Jefferies provided the financing commitment for the transaction and also advised Pamplona along with Perella Weinberg Partners. Based in Luxembourg, Alvogen is a pharmaceuticals company that produces and distributes generic, brand, OTC brands and biosimilar products.


Lone Star Funds agrees to buy DFC Global Corp for about $1.3 bln

DFC Global Corp said Wednesday that it has agreed to be acquired by Lone Star Funds for approximately $1.3 billion. According to terms of the agreement, DFC Global shareholders will receive $9.50 in cash for each share of DFC common stock they own. The deal is expected to be completed in the third quarter of 2014. Houlihan Lokey Capital advised DFC Global on the transaction while Jefferies was the lead financial advisor to Lone Star Funds. Jefferies Finance and Credit Suisse are providing debt financing for the acquisition. DFC Global Corp. is a provider of alternative financial services.


GTCR’s Sterigenics agrees to buy Nordion for about $727 mln

Sterigenics, a portfolio company of GTCR, has agreed to acquire Nordion for approximately $727 million. According to the agreement, shareholders will receive a cash consideration of $11.75 per share. Jefferies is advising Nordion on the transaction. Based in Ottawa, Ontario, Nordion is a provider of products and services for the health science sector.


Sirius agrees to buy Stratus for about $352 million

Sirius Capital Group has agreed to acquire Stratus Technologies for approximately $352 million. Jefferies advised Stratus on the transaction while Wells Fargo Securities and Macquarie Capital are serving as M&A advisors to Siris. Based in Maynard, Mass., Stratus Technologies is a provider of availability solutions.

VC-backed Syndax Pharmaceuticals files for IPO

Syndax Pharmaceuticals has filed for an IPO. The number of shares that will be offered as well as the stock’s pricing terms have yet to be set. Deutsche Bank Securities and Jefferies are serving as lead underwriters. Headquartered in Waltham, Mass., Syndax is a Syndax Pharmaceuticals is a developer of epigenetic therapies for treatment-resistant cancers. Its backers include Domain Associates, MPM Capital, Forward Ventures, Pappas Ventures and Avalon Ventures.


PE-backed Papa Murphy’s Holdings files for IPO

Papa Murphy’s Holdings has filed for an IPO. The number of shares that will be offered as well as the pricing terms have yet to be set. The stock will list on the NASDAQ under the ticker symbol “FRSH.” Jefferies, Robert W. Baird & Co. and Wells Fargo Securities will serve as the lead underwriters. Based in Vancouver, Washington, Papa Murphy’s Holding, which is backed by Lee Equity Partners, is a pizza chain franchisor.

VC-backed Aquinox Pharmaceuticals raises $46.2 mln for IPO

Aquinox Pharmaceuticals has raised $46.2 million for its IPO after pricing its 4.2 million shares at $11 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “AGXP.” Jefferies and Cowen and Company are the lead underwriters. Based in Vancouver, British Columbia, Aquinox Pharmaceuticals is a clinical stage pharmaceutical company focused on treating inflammatory disease and cancer. Its backers include Pfizer Venture Investments, Ventures West, Johnson & Johnson and Augment Investments.

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget